Novavax, Inc.Short
$NVAX #nvax $24 target by 12/9/2024
Novavax, NVAX phase 3 trial begins on 12/9/2024. ctv.veeva.com/study/phase-3-study-of-the-safety-and-immunogenicity-of-covid-19-and-influenza-combination-vaccine A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine
NVAX phase 3 trial begins on 12/9/2024. ctv.veeva.com/study/phase-3-study-of-the-safety-and-immunogenicity-of-covid-19-and-influenza-combination-vaccine A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.